Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).
Status:
Withdrawn
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
SDF-1, an important cytokine for neovascularisation is cleaved by (dipeptidyl peptidase IV)
DPPIV.
The aim of this study is to assess the effect of the dipeptidyl peptidase IV inhibitor
vildagliptin (Galvus®) on endothelial function as well as number and functional activity of
progenitor cells in patients with documented diabetes mellitus.